Blood Sugar News and Research

RSS

Blood sugar concentration, or glucose level, refers to the amount of glucose present in the blood of a human or animal. Normally, in mammals the blood glucose level is maintained at a reference range between about 3.6 and 5.8 mM (mmol/l). It is tightly regulated as a part of metabolic homeostasis.

Global cancer cases and deaths expected to soar by 2050 despite advances in treatment

There has been a rapid increase in the global number of cancer cases and deaths between 1990 and 2023, despite advances in cancer treatment and efforts to tackle cancer risk factors over that same time period.

24 Sep 2025

Orforglipron pill improves heart and metabolic risk factors in trial

Patients taking an experimental oral GLP-1 drug lost significant weight and improved their heart and metabolic risk factors in a large, international, phase 3 clinical trial led by investigators at Weill Cornell Medicine, McMaster University, York University and other institutions.

22 Sep 2025

Study points to a surprising new ally in the fight against type 2 diabetes

A new study from Duke University School of Medicine is challenging long-standing views on blood sugar regulation - and pointing to a surprising new ally in the fight against type 2 diabetes.

19 Sep 2025

Oral drug baricitinib shows promise in slowing early type 1 diabetes progression

In 2023, the groundbreaking Australian BANDIT (Baricitinib in New Onset Type 1 Diabetes) trial [1] reported that a daily pill of baricitinib, commonly prescribed for rheumatoid arthritis and alopecia, could safely preserve the body's own insulin production and slow the progression of type 1 diabetes (T1D) in people recently diagnosed with the condition.

19 Sep 2025

Verapamil shows potential for preserving beta-cell function in type 1 diabetes

New research (the Ver-A-T1D trial) presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15-19 September) shows that slow-release (SR) verapamil (360mg daily) could have a potential effect on beta-cell function in adults with newly diagnosed type 1 diabetes.

18 Sep 2025

Oral GLP-1 drug orforglipron achieves significant weight loss in global trial

Patients taking an experimental oral GLP-1 drug lost significant weight and improved their heart and metabolic risk factors in a large, international, phase III clinical trial led by investigators at Weill Cornell Medicine, McMaster University, York University and other institutions

18 Sep 2025

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.

18 Sep 2025

Evening meals hold the key to morning glucose control in prediabetes

The way glucose is regulated at night plays a key role in fasting glucose levels the next morning, when blood sugar is expected to be at its lowest.

18 Sep 2025

Cholesterol control improves but cardiovascular disease still increases in Mexico

Despite improved statin use and cholesterol control, cardiovascular disease risk rose in Mexico between 2016 and 2023, according to a study being presented at ACC Latin America 2025 that used region-specific tools to more accurately predict the local disease burden.

18 Sep 2025

Scientists unveil new obesity drug that reprograms fat and energy use

Details of a new drug that aims to treat the underlying causes of obesity are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September).

18 Sep 2025

Peroxisomes identified as alternative heat producers in brown fat

Researchers at Washington University School of Medicine in St. Louis have identified a novel way brown fat - an energy-burning form of fat - can rev the body's metabolic engine, consuming cellular fuel and producing heat in a way that improves metabolic health.

17 Sep 2025

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.

17 Sep 2025

GLP-1 drugs found to protect against diabetic retinopathy

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Pharmaceutics.

17 Sep 2025

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated with GLP-1 receptor agonist medicines alone.

16 Sep 2025

Younger adults and men with type 2 diabetes face higher risk of sepsis

Living with type 2 diabetes (T2D) may double the risk of developing sepsis-with those aged younger than 60 years and men particularly susceptible, according to a long-term community-based study in Australia, being presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Vienna (15-19 Sept).

16 Sep 2025

Ketogenic diets may lower migraine frequency and medication use

This narrative review argues that the migraine brain is hypometabolic, with converging evidence of mitochondrial dysfunction, impaired glucose handling, neuroinflammation, microbiome shifts, and obesity-related pathways. It proposes ketogenic diets as a plausible preventive strategy that may reduce monthly migraine days and medication use, while emphasizing the need for larger, rigorous randomized trials and careful clinical oversight.

14 Sep 2025

Are GLP-1 drugs safe for women planning pregnancy?

A study reveals rising GLP-1 prescriptions in young women, highlighting low contraception use and potential risks for unintended pregnancies and fetal outcomes.

12 Sep 2025

Weill Cornell Medicine receives $3.4 million NIH grant to study type 1 diabetes development

Weill Cornell Medicine has received a four-year, $3.4 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, for a study of the details and dynamics of the autoimmune process that causes type 1 diabetes.

11 Sep 2025

Research warns of lasting health impacts from muscle loss in young cancer patients

New research from the Exercise Medicine Research Institute at Edith Cowan University (ECU) has highlighted that children undergoing cancer treatment often lose skeletal muscle at a time when they should be rapidly gaining it, a loss that could increase treatment complications and raise the risk of long-term health problems.

10 Sep 2025

Diabetes remains undiagnosed and untreated among a large portion of the global population

A large portion of the global population with diabetes remains undiagnosed or is not receiving optimal care, according to a new study published in The Lancet Diabetes & Endocrinology.

9 Sep 2025

Blood Sugar News and Research

Further Reading

Global cancer cases and deaths expected to soar by 2050 despite advances in treatment

Orforglipron pill improves heart and metabolic risk factors in trial

Study points to a surprising new ally in the fight against type 2 diabetes

Oral drug baricitinib shows promise in slowing early type 1 diabetes progression

Verapamil shows potential for preserving beta-cell function in type 1 diabetes

Oral GLP-1 drug orforglipron achieves significant weight loss in global trial

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

Evening meals hold the key to morning glucose control in prediabetes

Cholesterol control improves but cardiovascular disease still increases in Mexico

Scientists unveil new obesity drug that reprograms fat and energy use

Peroxisomes identified as alternative heat producers in brown fat

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

GLP-1 drugs found to protect against diabetic retinopathy

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

Younger adults and men with type 2 diabetes face higher risk of sepsis

Ketogenic diets may lower migraine frequency and medication use

Are GLP-1 drugs safe for women planning pregnancy?

Weill Cornell Medicine receives $3.4 million NIH grant to study type 1 diabetes development

Research warns of lasting health impacts from muscle loss in young cancer patients

Diabetes remains undiagnosed and untreated among a large portion of the global population

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News